The **Nasdaq-100 Index** has been reconstituted and will be effective from Dec. 22, adding six new companies while removing six others. Nasdaq's venture into **tokenized stocks** could revolutionize stakeholder implications with **note tender offers**. Financial institutions like Barclays still uphold their **buy rating** for Nasdaq (NDAQ), despite a price cut. Meanwhile, there is mixed sentiment regarding Nasdaq's **valuation**, viewed in conjunction with its Q3 results and budding fintech efforts. Investment management firms have been increasingly placing their chips on Nasdaq, with **Brevan Howard CCP**, **Eventide Asset Management LLC**, and **Cerity Partners LLC** among others purchasing new stakes. On the other hand, **State Street Corp** and **The Manufacturers Life Insurance Company** reduced their stock positions in Nasdaq. Nasdaq experienced a marginal drop (1.6%) post its last earnings release, and the market anticipates better earnings in the coming periods. On a brighter note, Nasdaq's five-year shareholders have enjoyed returns of 125%, despite recent trading ranges indicating an undervalued stock. The venture into **tokenized stocks** and partnership with **Revolut** for expanded **RegTech** aids in reshaping Nasdaq's strategic positioning. There is analyst optimism about Nasdaq's future despite experiencing recent dips. The stock continues to stay attractive for growth investors, while consistently delivering strong earnings.
Nasdaq NDAQ News Analytics from Tue, 08 Apr 2025 07:00:00 GMT to Sat, 13 Dec 2025 23:41:06 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor 2
